DiaMedica Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$34.4M | -$26.7M | -$21.3M | -$14.0M | -$13.6M |
| Operating expenses | $34.4M | $26.7M | $21.3M | $14.0M | $13.6M |
| Cash from operations | -$29.1M | -$22.1M | -$18.7M | -$11.5M | -$12.3M |
| Capital expenditure | $40,000 | $25,000 | $24,000 | $81,000 | $22,000 |
| Free cash flow | -$29.1M | -$22.1M | -$18.8M | -$11.6M | -$12.3M |
| Total assets | $61.4M | $46.3M | $54.2M | $34.4M | $45.6M |
Shares outstanding 53.9M · Free float 42.6%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.